EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Population pharmacokinetics of adebrelimab – Support of alternative flat dose regimen in extensive‐stage small‐cell lung cancer

Peng Chen, Yanyan Zhang, Yike Wang, Ke Ma, Wei Shi, Nassim Djebli iD, Kai Shen

CPT: Pharmacometrics & Systems Pharmacology · 2024

DOI: 10.1002/psp4.13155 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2024. Verfasst von Peng Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology Department, Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Antibodies, Monoclonal, Humanized, Small Cell Lung Carcinoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adebrelimab, a novel anti‐PD‐L1 antibody, has been approved by the National Medical Products Administration of China as an intravenous infusion for use in combination with carboplatin and etoposide as first‐line treatment for extensive‐stage small‐cell lung cancer in 2023. A two‐compartment model with empirical time‐varying CL for adebrelimab was established based on data from 263 patients receiving body weight‐based doses from two clinical studies. Significant covariate effects of baseline body weight, albumin levels, tumor size, neutrophil counts, and presence of anti‐drug antibodies were identified on CL of debrelimab, none of which were clinically significant or warranted dose adjustment. The degree of decrease in CL was higher in patients who responded to treatment with adebrelimab than in non‐responders. Adebrelimab exposures (AUC, C trough , or C max ) were not identified as a statistically significant factor related to efficacy or safety endpoint in the exposure–response analysis. Distribution of simulated exposure metrics from the flat dose regimen (1200 mg q3w) was similar to the marketed weight‐based dosing regimen (20 mg/kg q3w), supporting the alternative flat dose regimen in the clinic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsAntibodies, Monoclonal, HumanizedSmall Cell Lung CarcinomaHumansMiddle AgedFemaleMaleAgedAntineoplastic Combined Chemotherapy ProtocolsAdultModels, BiologicalCarboplatinDose-Response Relationship, DrugEtoposideAged, 80 and overInfusions, Intravenous

Substanzen

Antibodies, Monoclonal, HumanizedCarboplatinEtoposide

Autor:innen und Institutionen

  • Clinical Pharmacology Department, Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China.
  • Oncology Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China.
  • Clinical Pharmacology Department, Luzsana Biotechnology/Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China.

ORCID-Profile: Nassim Djebli

Zitieren

APA

Chen, P., Zhang, Y., Wang, Y., Ma, K., Shi, W., Djebli, N., & Shen, K. (2024). Population pharmacokinetics of adebrelimab – Support of alternative flat dose regimen in extensive‐stage small‐cell lung cancer. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.13155

Vancouver

Chen P, Zhang Y, Wang Y, Ma K, Shi W, Djebli N, et al. Population pharmacokinetics of adebrelimab – Support of alternative flat dose regimen in extensive‐stage small‐cell lung cancer. CPT: Pharmacometrics & Systems Pharmacology. 2024. doi:10.1002/psp4.13155

BibTeX
@article{Chen2024,
  author = {Chen, Peng and Zhang, Yanyan and Wang, Yike and Ma, Ke and Shi, Wei and Djebli, Nassim and Shen, Kai},
  title = {Population pharmacokinetics of adebrelimab – Support of alternative flat dose regimen in extensive‐stage small‐cell lung cancer},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2024},
  doi = {10.1002/psp4.13155}
}
Kostenlos starten →